NEW YORK (GenomeWeb News) – GenomeQuest and Pathogenica today announced a partnership to offer discovery services in infectious disease research.
The deal combines Pathogenica's technology for detecting and sub-selecting pathogen genomes in human tissue with GenomeQuest's large-scale whole genome, exome, and microbiome analysis. Services to be offered include research into the interaction between the human microbiome and human genome, the firms said.
GenomeQuest and Pathogenica will immediately begin work on target selection, assay customization, and validation studies, they said.
Target applications will span basic research through clinical trial endpoint evaluation and focus on infection therapeutics in which the genotypes of both the pathogen and human affect the treatment outcome. Applications of the research-use only offerings include viral drug resistance studies in pre-clinical and clinical development; and co-sequencing of viral drug resistance mutations and human exome samples to predict drug response.
They also include custom infectious disease assays combined with deep sequencing and analysis for the identification of mutant infectious strains in human and mouse samples; and development of biomarkers for infectious disease.
Financial and other terms of the deal were not disclosed.